Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chimerix Inc (NQ: CMRX )

0.8750 +0.0150 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 177,994
Open 0.8600
Bid (Size) 0.8750 (1)
Ask (Size) 0.8800 (15)
Prev. Close 0.8600
Today's Range 0.8550 - 0.8900
52wk Range 0.7500 - 1.300
Shares Outstanding 86,249,744
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire

Performance

YTD
-8.85%
-8.85%
1 Month
-16.67%
-16.67%
3 Month
-1.69%
-1.69%
6 Month
-11.62%
-11.62%
1 Year
-17.45%
-17.45%

More News

Read More
CMRX Stock Earnings: Chimerix Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024
Via InvestorPlace
Earnings Scheduled For February 29, 2024
Via Benzinga
Preview: Chimerix's Earnings
Via Benzinga
Earnings Outlook For Chimerix
Via Benzinga
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Via FinancialNewsMedia
Exposures COVID-19
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
From FN Media Group LLC
Via GlobeNewswire
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Appoints Marc D. Kozin to Board of Directors
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Appoints Lisa Decker to Board of Directors
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.